M

akers of over-the-counter drugs may soon pay for federal review of their products, just like pharmaceutical makers. And they’re fine with the change.

After years of discussion, the Food and Drug Administration appears poised to make that change as part of a sweeping overhaul of its regulations for OTC products. But during a stakeholder meeting on the topic Wednesday afternoon, it was clear that many specifics about the program will be foggy until Congress acts.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy